The outcomes of treatment with gemtuzumab ozogamicin compared with those of conventional chemotherapy for relapse of acute myelogenous leukemia (AML) were studied. The gemtuzumab ozogamicin group ...

b Percentages do not total 100 because of rounding. c Significantly different from the corresponding value for the gemtuzumab ozogamicin group (p < 0.001). d p < 0.001. e Patients not treated in ...